Newman Dignan & Sheerar Inc. reduced its position in Bristol-Myers Squibb Company (NYSE:BMY) by 0.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,274 shares of the biopharmaceutical company’s stock after selling 209 shares during the quarter. Bristol-Myers Squibb makes up 1.0% of Newman Dignan & Sheerar Inc.’s portfolio, making the stock its 27th largest holding. Newman Dignan & Sheerar Inc.’s holdings in Bristol-Myers Squibb were worth $1,798,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of BMY. Terra Nova Asset Management LLC lifted its position in Bristol-Myers Squibb by 8.3% in the first quarter. Terra Nova Asset Management LLC now owns 10,334 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 794 shares during the period. Cobblestone Capital Advisors LLC NY lifted its holdings in shares of Bristol-Myers Squibb by 38.5% during the first quarter. Cobblestone Capital Advisors LLC NY now owns 13,279 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 3,690 shares during the period. NTV Asset Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 1.4% during the first quarter. NTV Asset Management LLC now owns 36,017 shares of the biopharmaceutical company’s stock valued at $1,958,000 after acquiring an additional 500 shares during the period. Altfest L J & Co. Inc. lifted its holdings in shares of Bristol-Myers Squibb by 9.3% during the first quarter. Altfest L J & Co. Inc. now owns 50,138 shares of the biopharmaceutical company’s stock valued at $2,726,000 after acquiring an additional 4,254 shares during the period. Finally, AT Bancorp lifted its holdings in shares of Bristol-Myers Squibb by 203.1% during the first quarter. AT Bancorp now owns 27,495 shares of the biopharmaceutical company’s stock valued at $1,495,000 after acquiring an additional 18,424 shares during the period. 69.51% of the stock is owned by hedge funds and other institutional investors.
BMY has been the subject of a number of research reports. BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a research note on Thursday, September 28th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://transcriptdaily.com/2017/11/18/newman-dignan-sheerar-inc-trims-position-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.32 on Friday. The stock has a market capitalization of $101,260.00, a PE ratio of 20.69, a PEG ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.54%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.